JOP20190187A1 - مترافقات عقار جسم مضاد لـ ccr7 - Google Patents

مترافقات عقار جسم مضاد لـ ccr7

Info

Publication number
JOP20190187A1
JOP20190187A1 JOP/2019/0187A JOP20190187A JOP20190187A1 JO P20190187 A1 JOP20190187 A1 JO P20190187A1 JO P20190187 A JOP20190187 A JO P20190187A JO P20190187 A1 JOP20190187 A1 JO P20190187A1
Authority
JO
Jordan
Prior art keywords
drug conjugates
antibody drug
antibodies
antigen binding
binding fragments
Prior art date
Application number
JOP/2019/0187A
Other languages
English (en)
Inventor
Shailaja Kasibhatla
Mark Knuth
Steven Bender
Sarah Rue
Sabine Rottmann
Anna Galkin
Tracy Charlton
Glen Spraggon
Bernhard Hubert Geierstanger
Scott Martin Glaser
Tetsuo Uno
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190187A1 publication Critical patent/JOP20190187A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

يقوم هذا الطلب بالكشف عن أجسام مضادة لـ CCR7، شظايا ربط مولد ضد منه، ومترافقات عقار جسم مضاد من الأجسام المضادة المذكورة أو شظايا ربط مولد ضد. يتعلق الاختراع أيضا بطرق علاج أو الوقاية من السرطان باستخدام الأجسام المضادة، شظايا ربط مولد ضد، ومترافقات عقار جسم مضاد. تم هنا أيضا الكشف عن طرق صنع الأجسام المضادة، شظايا ربط مولد ضد، ومترافقات عقار جسم مضاد، وطرق استخدام الأجسام المضادة وشظايا ربط مولد ضد كعوامل تشخيصية.الشكل 10
JOP/2019/0187A 2017-02-03 2017-06-16 مترافقات عقار جسم مضاد لـ ccr7 JOP20190187A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762454476P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
JOP20190187A1 true JOP20190187A1 (ar) 2019-08-01

Family

ID=61283268

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0187A JOP20190187A1 (ar) 2017-02-03 2017-06-16 مترافقات عقار جسم مضاد لـ ccr7

Country Status (25)

Country Link
US (2) US11634497B2 (ar)
EP (1) EP3577139A1 (ar)
JP (1) JP7312111B2 (ar)
CN (1) CN110248963B (ar)
AR (1) AR110920A1 (ar)
AU (1) AU2018215701B2 (ar)
BR (1) BR112019015950A2 (ar)
CA (1) CA3049639A1 (ar)
CL (1) CL2019002144A1 (ar)
CO (1) CO2019008209A2 (ar)
CR (1) CR20190346A (ar)
CU (1) CU24648B1 (ar)
EA (1) EA201991763A1 (ar)
EC (1) ECSP19054235A (ar)
IL (1) IL267834B2 (ar)
JO (1) JOP20190187A1 (ar)
MA (1) MA51778A (ar)
MX (2) MX2019009119A (ar)
MY (1) MY194997A (ar)
PE (1) PE20191328A1 (ar)
PH (1) PH12019501773A1 (ar)
SG (1) SG11201906229QA (ar)
TW (1) TW202323292A (ar)
UY (1) UY37591A (ar)
WO (1) WO2018142322A1 (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN110352074A (zh) 2017-02-28 2019-10-18 西雅图遗传学公司 用于偶联的半胱氨酸突变抗体
AU2019406199A1 (en) * 2018-12-21 2021-07-29 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
BR112022006632A2 (pt) * 2019-10-09 2022-06-28 Catapult Therapeutics B V Uso de um anticorpo anti-ccr7 em terapias de combinação com um inibidor de btk e/ou inibidor de bcl2 para tratamento de malignidades hematológicas
US20220403023A1 (en) * 2019-10-25 2022-12-22 WuXi Biologics Ireland Limited Novel anti-cd47 antibodies and uses thereof
EP4126066A4 (en) 2020-03-27 2024-04-24 Avidity Biosciences Inc COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
BR112023001359A2 (pt) 2020-07-27 2023-02-14 Tuojie Biotech Shanghai Co Ltd Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
EP4240765A2 (en) * 2020-11-06 2023-09-13 Novartis AG Antibody fc variants
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20230161759A (ko) * 2022-05-19 2023-11-28 국민대학교산학협력단 Ccr7의 활성 조절 항체

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2128208C (en) 1992-11-17 2004-01-06 Ronald Godiska Novel seven transmembrane receptors
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6043551A (en) 1997-09-30 2000-03-28 Intel Corporation Metal locking structures to prevent a passivation layer from delaminating
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6153441A (en) 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69907456T2 (de) 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
IL140893A0 (en) 1998-07-22 2002-02-10 Osprey Pharmaceuticals Ltd Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000009151A1 (en) 1998-08-17 2000-02-24 Schering Corporation Regulation of dendritic cell trafficking
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
AU1488501A (en) 1999-11-24 2001-06-04 Schering Corporation Methods of inhibiting metastasis
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU2001280891A1 (en) 2000-08-01 2002-02-13 Schering Corporation Uses of mammalian genes and related reagents
US6411163B1 (en) 2000-08-14 2002-06-25 Intersil Americas Inc. Transconductance amplifier circuit
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
WO2002067771A2 (en) 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US20020168358A1 (en) 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE60216606T2 (de) 2001-06-07 2007-04-05 Chemocentryx Inc., Mountain View Zellwanderungsassay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004104574A2 (en) 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
ITRM20030386A1 (it) 2003-08-05 2005-02-06 Istituto Naz Per Le Malattie Infettive Lazz Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
US7274964B2 (en) 2004-04-16 2007-09-25 Bal Seal Engineering Co., Inc. Use of an axial canted coil spring as an electrical contact to minimize resistivity variations under dynamic loads
SI1778718T1 (sl) 2004-07-02 2015-01-30 Genentech, Inc. Inhibitorji IAP
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
WO2006056061A1 (en) 2004-11-24 2006-06-01 Val-Chum, S.E.C. Methods to identify, prepare, and use naive t cell recent thymic emigrants
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2588921C (en) 2004-12-20 2015-10-20 Genentech, Inc. Pyrrolidine inhibitors of iap
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US20060182750A1 (en) 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
EP1866421A2 (en) 2005-03-09 2007-12-19 Board of Regents, The University of Texas System Methods and composition related to in vivo imaging of gene expression
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2617539A1 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
US8795674B2 (en) 2005-09-30 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for modulating immune tolerance
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
WO2007055823A2 (en) 2005-10-28 2007-05-18 Multispan, Inc. Gpcr expressing cell lines and antibodies
JO2660B1 (ar) 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
BRPI0711237A2 (pt) 2006-05-23 2011-08-23 Vb Medicare Pvt Ltd processo de purificação e recuperação de uma amida terciária a partir de uma composição lìquida aquosa
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
MX2009007021A (es) 2006-12-29 2009-08-07 Osprey Pharmaceuticals Usa Inc Metodos para seleccionar y producir toxinas modificadas, conjugados que contienen toxinas modificadas y usos de los mismos.
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
PE20140100A1 (es) 2007-09-12 2014-02-12 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
EP2073009A1 (en) 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
MY157165A (en) 2008-04-30 2016-05-13 Immunogen Inc Cross-linkers and their uses
WO2009139853A2 (en) 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2010027828A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
US8276780B2 (en) 2009-11-18 2012-10-02 Snyder Industries, Inc. Fitting torque arm restraint
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011123903A1 (en) 2010-04-08 2011-10-13 Adelaide Research & Innovation Pty Ltd Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof
CA2813203C (en) 2010-09-28 2022-10-18 Sekisui Chemical Co., Ltd. Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2012148547A1 (en) 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
EP2691117A2 (en) 2011-03-29 2014-02-05 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
CN103857421B (zh) 2011-06-13 2017-09-22 Tla指标免疫疗法公司 治疗癌症的方法和在其中使用的结合试剂
WO2012172337A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
WO2012172343A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
WO2012172346A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating respiratory conditions
EP3176583B1 (en) 2011-06-13 2019-09-11 TLA Targeted Immunotherapies AB Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome
RU2011130448A (ru) 2011-07-22 2013-01-27 Зао "Евроген" Методы и наборы для увеличения разнообразия т-клеток
SG190466A1 (en) 2011-11-18 2013-06-28 Agency Science Tech & Res Methods for diagnosis and/or prognosis of ovarian cancer
EP2814525A1 (en) 2012-02-13 2014-12-24 Cook Medical Technologies LLC Medical devices for collecting pathogenic cells
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
JP6321633B2 (ja) 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
WO2013184200A1 (en) * 2012-06-05 2013-12-12 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr7
US20150307619A1 (en) 2012-12-13 2015-10-29 The Schepens Eye Research Institute, Inc. Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
US9999680B2 (en) * 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9498543B2 (en) 2013-03-15 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970483A2 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
US9719504B2 (en) 2013-03-15 2017-08-01 Integrated Designs, L.P. Pump having an automated gas removal and fluid recovery system and method
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
WO2015033137A1 (en) 2013-09-04 2015-03-12 Imperial Innovations Limited Biological methods and materials for use therein
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
EP3753578A1 (en) 2013-12-17 2020-12-23 Novartis AG Cytotoxic peptides and conjugates thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SG11201606850QA (en) 2014-03-12 2016-09-29 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US10758568B2 (en) 2014-04-16 2020-09-01 Genovie Ab Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
PL3151865T3 (pl) * 2014-05-22 2022-01-03 Byondis B.V. Koniugacja w określonym miejscu leków-łączników z przeciwciałami oraz powstałe w jej wyniku koniugaty przeciwciało-lek (ADCs)
WO2015189791A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
WO2016075670A1 (en) * 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
EP3234307B1 (en) * 2014-12-17 2019-11-20 National Oilwell DHT, L.P. Method of pressure testing a wellbore
WO2016179472A2 (en) 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
EP3411965B1 (en) * 2016-02-01 2020-04-08 Telefonaktiebolaget LM Ericsson (publ) Reconfigurable optical modulator
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7

Also Published As

Publication number Publication date
CR20190346A (es) 2019-09-13
SG11201906229QA (en) 2019-08-27
CN110248963A (zh) 2019-09-17
AU2018215701A1 (en) 2019-07-18
MX2022011732A (es) 2022-10-13
UY37591A (es) 2018-08-31
CN110248963B (zh) 2023-12-26
TW202323292A (zh) 2023-06-16
RU2019126481A (ru) 2021-03-03
CA3049639A1 (en) 2018-08-09
ECSP19054235A (es) 2019-08-30
US20240092918A1 (en) 2024-03-21
RU2019126481A3 (ar) 2021-07-08
AR110920A1 (es) 2019-05-15
JP2020506703A (ja) 2020-03-05
EA201991763A1 (ru) 2019-12-30
CU20190072A7 (es) 2020-03-04
CO2019008209A2 (es) 2019-09-09
MX2019009119A (es) 2019-11-21
PE20191328A1 (es) 2019-09-24
IL267834A (en) 2019-09-26
CL2019002144A1 (es) 2019-10-11
US20200216548A1 (en) 2020-07-09
EP3577139A1 (en) 2019-12-11
MA51778A (fr) 2019-12-11
AU2018215701B2 (en) 2021-04-22
TW201831510A (zh) 2018-09-01
WO2018142322A1 (en) 2018-08-09
BR112019015950A2 (pt) 2020-04-07
MY194997A (en) 2022-12-30
PH12019501773A1 (en) 2020-06-29
IL267834B2 (en) 2024-01-01
CU24648B1 (es) 2023-02-13
JP7312111B2 (ja) 2023-07-20
US11634497B2 (en) 2023-04-25
IL267834B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
PH12017500890A1 (en) Antibody drug conjugates
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
WO2018069871A3 (en) Anti-kras binding proteins
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
EA201990218A1 (ru) Антитела с низкой иммуногенностью и их применения
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.